E-cd、cat的表达与上皮性卵巢癌预后的关系

目的 探讨上皮钙粘附素(E—cd)、连环素(cat)的表达在估测上皮性卵巢癌(EOC)预后中的价值。方法 采用免疫组化SABC法检测44例EOC组织中E—cd、α—cat、β-cat、γ-cat蛋白的表达情况，分析其与患者预后的关系。结果 E—cd和cat的异常表达均与EOC的病理分级有显著相关性，E—cd、γ-cat的异常表达与患者的生存时间显著相关。结论 检测EOC中E—cd、cat的表达有助于了解EOC的生物学行为，并可作为估测EOC预后的重要指标。     

上皮性卵巢癌组织POSTN、COL11A1表达变化及其与临床病理特征和预后的关系

目的 探讨上皮性卵巢癌(EOC)组织骨膜蛋白(POSTN)、Ⅺ型胶原α1(COL11A1)表达变化及其与临床病理特征和预后的关系。方法 选择EOC组织122例份、正常输卵管上皮组织60例份,采用免疫组化法检测POSTN、COL11A1蛋白表达。采用Spearman秩相关分析法分析EOC组织POSTN、COL11A1蛋白表达的关系。分析EOC组织POSTN、COL11A1蛋白阳性表达与临床病理特征的关系。绘制Kaplan-Meier生存曲线,分析EOC组织POSTN、COL11A1表达与预后的关系。结果 EOC组织POSTN、COL11A1蛋白阳性表达率均高于正常输卵管上皮组织(χ²分别为30.118、22.499,P均<0.01)。Spearman秩相关分析显示,EOC组织POSTN蛋白表达与COL11A1蛋白表达呈正相关关系(r=0.722,P<0.05)。FIGO分期Ⅲ期、有淋巴结转移的EOC组织POSTN和COL11A1蛋白阳性表达率高于FIGO分期Ⅰ、Ⅱ期及无淋巴结转移的EOC组织(P均<0.05)。POSTN蛋白阳性表达者与阴性表达者3...     

上皮性卵巢癌与抑癌基因PTEN的关系

研究显示[1],PTEN基因既有蛋白酪氨酸磷酸酶活性,又有双重特异性磷酸酶活性,不仅能诱导细胞凋亡及抑制细胞有丝分裂,而且作用于调节细胞的黏附、转移和分化等.本研究着重观察上皮性卵巢癌中PTEN的表达,探讨PTEN在卵巢癌发生、发展中的作用.     

增殖细胞核抗原判断上皮性卵巢癌预后的价值

增殖细胞核抗原（ＰＣＮＡ）是反映肿瘤细胞增殖状态的一个指标。我们测定了３３例上皮性卵巢癌患者癌组织标本的ＰＣＮＡ表达情况，旨在探讨ＰＣＮＡ表达与肿瘤临床分期、细胞分化程度、转移的关系，以及其预测卵巢癌预后的价值。１资料与方法３３份标本均为上皮性卵巢癌...     

上皮性卵巢癌患者血浆中的cDNA水平变化及意义

目的观察上皮性卵巢癌（EOC）患者血浆中的循环DNA（cDNA）水平变化,探讨其临床意义。方法收集38例EOC（恶性组）、25例良性上皮性卵巢肿瘤（良性组）和60例健康志愿者（健康对照组）的血浆样本,以微量基因组DNA抽提试剂盒抽提血浆中的cDNA,将血浆cDNA与荧光染料SYBRgreenⅠ按比例稀释并充分混匀后通过紫外与可见光成像分析系统定量。结果恶性组血浆cDNA为（625.38±526.84）μg/L,良性组为（93.86.6±82.45）μg/L,健康对照组为（17.40±9.17）μg/L;恶性组与其他两组比较,P均〈0.05。血浆cDNA水平与EOC有无伴发腹水及淋巴结转移有关（P均〈0.05）。结论 EOC患者血浆中的cDNA水平升高,检测血浆中的cDNA有助于EOC诊断和预后判断。     

YTHDF1和EIF3C在上皮性卵巢癌中的表达及临床意义

［摘要］　目的　分析YTH结构域N6-甲基腺嘌呤RNA结合蛋白F1（YTHDF1）和真核翻译起始因子3C（EIF3C）在上皮性卵巢癌（EOC）中的表达及临床意义。方法　回顾性分析2016年1月至2020年1月徐州医科大学附属医院初诊收治的130例EOC患者的临床资料,另选取同期因卵巢良性囊肿行手术治疗的70例患者的正常卵巢组织作为对照。采用实时荧光定量聚合酶链反应（RT-qPCR）检测组织中YTHDF1 mRNA和EIF3C mRNA表达水平。采用免疫组化染色检测组织中YTHDF1蛋白和EIF3C蛋白表达情况。采用Pearson相关分析探讨YTHDF1 mRNA与EIF3C mRNA表达水平的相关性。分析YTHDF1蛋白、EIF3C蛋白表达情况与EOC患者临床病理特征的关联性。采用Kaplan-Meier法绘制生存曲线。采用Cox回归分析EOC患者预后的影响因素。结果　EOC组织中YTHDF1 mRNA、EIF3C mRNA表达水平高于正常卵巢组织,差异有统计学意义(P<0.05)。EOC组织中YTHDF1蛋白、EIF3C蛋白阳性表达率高于正常卵巢组织,差异有统计学意义（P<0.05）。Pearson相关分析结果显示,EOC组织中YTHDF1 mRNA与EIF3C mRNA表达呈正相关（r=0.802,P<0.001）。EOC组织中YTHDF1蛋白、EIF3C蛋白表达情况与肿瘤FIGO分期、病理分级、淋巴结转移情况具有显著关联性（P<0.05）。YTHDF1阴性患者的生存预后优于阳性患者（log-rank检验： χ²=6.120,P=0.013）。EIF3C阴性患者的生存预后优于阳性患者（log-rank检验： χ²=10.610,P=0.001）。Cox回归分析结果显示,FIGO分期Ⅲ期、病理分级Ⅲ级、淋巴结转移、较高的CA125水平以及YTHDF1蛋白、EIF3C蛋白阳性表达是EOC患者不良预后的独立危险因素。结论　EOC组织中YTHDF1、EIF3C表达升高,与不良临床病理特征有关。YTHDF1和EIF3C是潜在的评估EOC预后的生物标志物。     

手术前NLR与上皮性卵巢癌预后的相关性

目的 研究术前外周血中性粒细胞/淋巴细胞比值(NLR)在上皮性卵巢癌(EOC)患者诊断及复发中的价值.方法 回顾性分析2011年1月至2014年1月遵义市第一人民医院收治的经手术治疗的EOC患者106例及良性卵巢肿瘤患者128例的临床资料.检测受检者的NLR水平;受试者工作特征曲线(ROC)确定EOC患者血中NLR最佳...     

ERCC1与RRM1在胰腺癌组织中的表达及临床意义

目的 研究胰腺癌、癌旁组织、正常胰腺组织中DNA损伤修复蛋白ERCC1,RRM1表达及其临床意义.方法 选取吉林大学第一医院2009年1月至2012年6月手术切除胰腺癌及癌旁组织34例,正常胰腺组织20例,标本经常规石蜡包埋,采用SABC法行免疫组化染色.结果 在胰腺癌组织中ERCC1高表达14例(4l.2％),RRM1高表达10例(29.4％),癌旁组高表达率分别为67.6％、52.9％,正常胰腺组织分别为70.0％、80.0％.两种基因的高表达率均低于癌旁组及正常胰腺组(P＜0.05).在有无淋巴结、肿瘤大小、分化程度因素中分析ERCC1及RRM1的高低表达无统计学差异.结论 ERCC1及RRM1基因的表达缺失与肿瘤的发生密切相关,其表达与否对肿瘤大小、分化程度、区域淋巴结转移等无显著影响.     

RRM1和ERCC1在非小细胞肺癌中的表达及意义

目的探讨DNA修复基因家族成员ERCCl、RRM1在非小细胞肺癌(NSCLC)中的表达及意义。方法应用免疫组织化学PV-9000法对30例NSCLC患者肿瘤组织中的ERCC1、RRM1蛋白表达进行检测。用χ2检验、相关分析、Kaplan-Meier生存曲线进行统计分析。结果 NSCLC患者肿瘤组织中,ERCC1和RRM1表达与患者性别、年龄、分期、病理类型、是否吸烟等参数无明显相关;ERCC1和RRM1的表达呈正相关(r=0.439,P=0.027);ERCC1阴性组的总生存期和无疾病进展生存期均明显长于ERCC1阳性组,RRM1阴性组的总生存期和无疾病进展生存期均明显长于RRM1阳性组(P<0.05或<0.01)。结论 ERCC1和RRM1在NSCLC肿瘤组织中的表达具有相关性,ERCC1和RRM1低表达提示NSCLC患者生存期长、生活质量高,RRM1和ERCC1高表达者对吉西他滨+顺铂化疗耐药,可作为判断其预后的指标,指导临床个体化用药。     

RRM1表达与上皮性卵巢癌预后的相关性分析

目的探讨核糖核苷酸还原酶大亚基（RRM1）在上皮性卵巢癌中的表达及其预后意义。方法采用免疫组化PV-6000二步法在62例上皮性卵巢癌组织中检测RRM1蛋白的表达,用Kaplan．Meier生存曲线和COX回归分析研究RRM1与上皮性卵巢癌预后的关系。结果RRM1蛋白阳性表达率低分化卵巢癌组高于高、中分化卵巢癌组（P〈0．05）;在早期上皮性卵巢癌患者中,RRM1阳性表达者生存率比阴性表达者高（P〈0．05）;而在晚期上皮性卵巢癌患者中,RRM1阳性表达者生存率低（P〈0．05）;RRM1阳性表达＋癌组织低分化为卵巢癌总生存期的影响因素,RRM1阳性表达＋癌组织低分化者死亡危险度是非RRM1阳性表达＋癌组织低分化者的4．252倍。结论RRM1对上皮性卵巢癌诊断及预后评估具有一定的价值。     

Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance

Background and purpose: Regimens containing platinum drugs continue to be amongst the most effective therapies for ovarian cancer. However, despite high initial response rates most patients relapse and die of their disease. Elevation of metallothionein has been implicated as a mechanism by which tumour cells become resistant to platinum anticancer drugs, although most of these studies have been carried out in vitro. This study was carried out to determine whether metallothionein expression was associated with response or survival in patients with epithelial ovarian cancer. Methods: Metallothionein was determined by radioimmune assay using frozen ovarian tumour tissue taken either before or following cytotoxic chemotherapy. Results: An increase in expression of metallothionein was seen in tumour tissue from patients who had undergone cytotoxic chemotherapy, although this did not attain significance. However, a preliminary study using biopsy material from the same patient, taken both before and after chemotherapy, showed a statistically significant increase in metallothionein. An analysis of these data showed that the level of metallothionein expression was not associated with survival or response. Conclusion: These data do not support the hypothesis that metallothionein expression is a determinant of response in ovarian cancer. There is some preliminary evidence from the study of paired samples which indicates that cytotoxic chemotherapy may increase metallothionein expression. An increase in metallothionein was also seen in the study using unmatched biopsies although this did not attain statistical significance, due in part to the large inter-patient variability in expression of this protein. Received: 24 January 2000 / Accepted: 3 April 2000     

胃癌中ERCC1、XRCC1表达与奥沙利铂化疗疗效之间的关系

目的观察胃癌组织中ERCC1、XRCC1的表达变化,探讨其与奥沙利铂化疗疗效的关系。方法采用免疫组化SP法检测80例胃癌患者术后胃癌组织中ERCC1、XRCC1的表达水平,患者术后全部采用FLO-FOX化疗方案,并采用2χ检验、Log-rank分析和Cox风险模型分析ERCC1、XRCC1在胃癌中的表达及其对奥沙利铂化疗疗效的影响。结果胃癌组织中ERCC1、XRCC1阳性率分别是72.50%（58/80）、45.00%（36/80）。Cox比例风险模型分析显示,胃癌组织中ERCC1表达、XRCC1表达、组织学分型和有无脉管癌栓是影响患者预后的独立因素。结论胃癌组织中的ERCC1、XRCC1表达水平与奥沙利铂化疗疗效有关。     

Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer

AIM: To evaluate the expression of galectin-1 and vascular endothelial growth factor (VEGF) in gastric cancer and investigate their relationships with clinicopathologic factors and prognostic significance. METHODS: Galectin-1 and VEGF were immunohistochemically investigated in tumor samples obtained from 214 gastric cancer patients with all tumor stages. Immunohistochemical analyses for galectin-1 and VEGF expression were performed on formalin-fixed, paraffin-embedded sections of surgical specimens. The relationship between the expression and staining intensity of galectin-1 and VEGF, clinicopathologic variables, and patient survival were analyzed. All patients underwent follow-up until cancer-related death or more than five years after tumor resection. P values < 0.05 were considered statistically significant.RESULTS: Immunohistochemical staining demonstrated that 138 of 214 gastric cancer samples (64.5%) were positive for galectin-1, and 116 out of 214 gastric cancer samples (54.2%) were positive for VEGF. There was a significant association between galectin-1 and VEGF expression; VEGF was detected in 60.1% of galectin-1-positive samples and 43.4% of galectin-1-negative samples (P < 0.05). Galectin-1 expression was associated with tumor size, tumor location, stage, lymph node metastases, and VEGF expression (all P < 0.05). VEGF expression was related to tumor size, stage, and lymph node metastases (all P < 0.05). The 5-year survival rate was 56.6% for galectin-1-positive patients and 69.2% for galectin-1-negative patients, and the prognosis for galectin-1-positive patients was significantly poorer compared with galectin-1-negative patients (χ 2 = 13.880, P = 0.000). The 5-year survival rates for VEGF-positive and VEGF-negative patients were 53.4% and 70.5%, respectively (χ2 = 4.619, P = 0.032). The overall survival rate of patients with both galectin-1 and VEGF overexpression in gastric cancer tissue samples was significantly poorer than other groups (both P < 0.05).CONCLUSION: Galectin-1 expr     

SDF-1／CXCR4在老年卵巢癌组织中的表达及意义

目的探讨趋化因子SDF-1及其受体CXCR4在老年人上皮性卵巢癌组织中的表达及意义。方法应用westernblotting方法定量检测43例老年患者上皮性卵巢癌组织中SDF-1和CXCR4的蛋白表达情况。结果老年人上皮性卵巢癌组织中SDF-1／CXCR4蛋白表达较卵巢良性肿瘤对照组明显增加,其相对表达量分别为（2．38±0．20）和（3．32±0．26）,差异具有统计学意义（P〈0．05）。结论SDF-1／CXCR4生物学轴可能在老年人卵巢癌的发生与转移过程中起着重要作用。     

The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis

Background: Immunotherapy has shown promise against solid tumors. However, the clinical significance of programmed cell death 1(PD-1) and programmed cell death ligand 1(PD-L1) in pancreatic ductal adenocarcinoma(PDAC) remains unclear. This meta-analysis aimed to analyze the prognostic effect of PD-L1 in PDAC.Data sources: Electronic search of the Pub Med, Cochrane Library and Web of Science was performed until December 2016. Through database searches, we identified articles describing the relationship between PD-L1 status and PDAC patient prognosis. Meta-analysis was performed to investigate the relationship between PD-1 and overall survival(OS).Results: Nine studies with 989 PDAC patients were included for PD-L1 expression analysis. And 5 studies with 688 PDAC patients were included in the prognostic analysis. The PD-L1 positive rate measured by immunohistochemistry(IHC) was higher than that measured by polymerase chain reaction(PCR)(P 0.001). PDAC patients with high expression levels of PD-L1 had significantly reduced OS(HR = 2.34;95% CI: 1.78–3.08). Subgroup analysis showed that the prognostic effect of PD-L1 levels was similar between the IHC and PCR methods. The PD-L1 positive rate was associated with PDAC T stages; the PD-L1 positive rate in the T3–4 group was higher than that in the T1-2 group(OR = 0.37; P = 0.001).Conclusions: High PD-L1 expression levels predicted a poor prognosis in PDAC patients. Thus, PD-L1 status helps determine treatment in PDAC patients.     

Expression of hENTl and ERCC1 genes in tumor tissues non-small cell lung cancer

ObjectiveTo investigate the expression of hENTl and ERCC1 genes in tumor tissues non–small cell lung cancer (NSCLC).MethodsFresh non–small lung cancer specimens were transplanted into nude mice. Twenty mice were randomized into two groups: experimental group receiving gemcitabine plus cisplatin and control group receiving 0.9% physiological saline. The expressions of hENTl and ERCC1 mRNA in tumor tissue were detected by real–time fluorescent quantitative PCR. The volume of tumor, the weight of nude mice and tumor volume were respectively measured and calculated 2–3 times per week. Tissue samples were collected from NSCLC mice treated with gemcitabine plus carboplatin.ResultsThe histological examination showed that many tumor cells were well preserved in nude mice. The rate of transplanted tumor cells was 86.7%. The concomitant treatment study showed that the rate of TV, RTV, T/C in GEM + DDP group was the lowest. LBP + DOC, DDP + DOC obviously influenced the body weight. Compared with NS group, DDP group, GEM group, the survival period and the level of hENTl of DDP+GEM group increased obviously, the level of ERCC1 decreased significantly (P<0.05).ConclusionsThe expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin.     

卵巢上皮性癌组织中EGFR、STAT3 mRNA的表达及意义

目的观察卵巢上皮性癌（卵巢癌）组织中表皮生长因子受体（EGFR）与信号转导和转录激活因子3（STAT3）mRNA的表达,并探讨其意义。方法用RT-PCR技术检测13例正常卵巢、11例卵巢良性肿瘤及43例卵巢癌组织中的EGFR mRNA和STAT3 mRNA。结果卵巢上皮性癌组织中EGFR、STAT3 mRNA阳性表达率显著高于正常卵巢及卵巢良性肿瘤组织（P均〈0.05）。卵巢上皮性癌组织中EGFR、STAT3 mRNA表达均与卵巢癌病理分期有关,与患者年龄、肿瘤分化程度、组织学类型及有无淋巴结转移等临床病理参数无关（P均〉0.05）;卵巢癌组织中EGFR和STAT3 mRNA表达有显著相关性（r=0.42,P〈0.01）。结论卵巢癌组织中EGFR、STAT3表达上调。二者在卵巢癌的发生发展中起重要作用。     

胃癌组织KAI 1和nm23-H1蛋白的表达意义

目的:观察胃癌组织中KAI 1和nm23-H1蛋白的表达与临床病理生物学的关系,探讨KAI 1蛋白在胃癌发生、发展中的作用．方法:应用兔抗人KAI 1多克隆抗体和鼠抗人nm23-H1 单克隆抗体对87例手术切除胃癌标本以PV-9000免疫组化二步法进行染色,用x2检验进行统计学分析．结果:伴有淋巴结转移的胃癌组织中KAI 1蛋白表达阳性率(60％,39／65)明显低于无淋巴结转移的胃癌组织(95％,21／22,P<0．05),早中期胃癌组织中KAI 1蛋白表达阳性率(94％,16／17)显著高于晚期胃癌组织(63％, 44／70,P<0．05),KAI 1蛋白高表达者其生存期亦较长 (P<0．05);伴有淋巴结转移的胃癌组织中nm23-H1蛋白表达阳性率明显低于无淋巴结转移的胃癌组织(18％ vs 77％,P<0．05),早中期胃癌组织nm23-H1蛋白表达阳性率明显高于晚期胃癌组织(65％vs26％,P<0．05)．结论:KAI 1和nm23-H1蛋白均与胃癌侵袭转移有关, 且KAI 1表达与胃癌患者预后密切相关,将两种指标联合检测,可作为正确判断胃癌患者预后,指导临床治疗的分子生物学指标．     

ZNRD1 might mediate UV irradiation related DNA damage and repair in human esophageal cancer cells by regulation of ERCC1

The downregulation of zinc ribbon domain‐containing 1 (ZNRD1) protein was recently found to partially reverse the resistance of human leukemia cells toward chemical therapeutic drugs. Therefore, the ZNRD1 protein might be involved in the process of DNA damage and repair. To explore the possible protective effects of ZNRD1 on DNA damage induced by ultraviolet (UV)‐C irradiation in human esophageal squamous cancer cell line EC109, we designed and transfected a expression vector into EC109 cells, and established an overexpression cell line. The single‐cell gel electrophoresis (comet assay) was used to investigate the DNA damage and repair in UV‐C‐irradiated control and transfected cells. It was found that the ZNRD1‐expressing cells exhibited a significant enhanced DNA repair capacity. Moreover, the overexpression of ZNRD1 could upregulate the expression of excision repair cross‐complementing 1 (ERCC1) gene. Collectively, these findings suggested that ZNRD1 might play an important role in the process of DNA damage and repair by regulating the expression of ERCC1.